TRxADE HEALTH Management

Management criteria checks 3/4

TRxADE HEALTH's CEO is Suren Ajjarapu, appointed in Jan 2014, has a tenure of 10.25 years. total yearly compensation is $414.23K, comprised of 85.5% salary and 14.5% bonuses, including company stock and options. directly owns 27.46% of the company’s shares, worth $2.34M. The average tenure of the management team and the board of directors is 9.9 years and 8.8 years respectively.

Key information

Suren Ajjarapu

Chief executive officer

US$414.2k

Total compensation

CEO salary percentage	85.5%
CEO tenure	10.3yrs
CEO ownership	27.5%
Management average tenure	9.9yrs
Board average tenure	8.8yrs

Recent management updates

Recent updates

Trxade Group GAAP EPS of -$0.13 misses by $0.05, revenue of $3.3M beats by $0.37M

Jul 25

Will TRxADE HEALTH (NASDAQ:MEDS) Spend Its Cash Wisely?

Mar 30

Here's Why We're Watching TRxADE HEALTH's (NASDAQ:MEDS) Cash Burn Situation

Nov 23

Need To Know: Analysts Just Made A Substantial Cut To Their TRxADE HEALTH, Inc. (NASDAQ:MEDS) Estimates

Jul 29

Pharma Pain Points - Trxade CEO Suren Ajjarapu (Video)

Jun 16

SpartanNash and Bonum Health join hands to provide telemedicine services

Jun 07

Shareholders Will Probably Hold Off On Increasing Trxade Group, Inc.'s (NASDAQ:MEDS) CEO Compensation For The Time Being

May 22

Earnings Release: Here's Why Analysts Cut Their Trxade Group, Inc. (NASDAQ:MEDS) Price Target To US$10.00

Apr 28

Time To Worry? Analysts Just Downgraded Their Trxade Group, Inc. (NASDAQ:MEDS) Outlook

Apr 01

Did Business Growth Power Trxade Group's (NASDAQ:MEDS) Share Price Gain of 143%?

Feb 05

CEO Compensation Analysis

How has Suren Ajjarapu's remuneration changed compared to TRxADE HEALTH's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-US$4m
Jun 30 2023	n/a	n/a	-US$4m
Mar 31 2023	n/a	n/a	-US$3m
Dec 31 2022	US$414k	US$354k	-US$3m
Sep 30 2022	n/a	n/a	-US$3m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$388k	US$372k	-US$5m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	-US$3m
Dec 31 2020	US$667k	US$286k	-US$3m
Sep 30 2020	n/a	n/a	-US$719k
Jun 30 2020	n/a	n/a	-US$830k
Mar 31 2020	n/a	n/a	-US$229k
Dec 31 2019	US$750k	US$250k	-US$284k
Sep 30 2019	n/a	n/a	US$23k
Jun 30 2019	n/a	n/a	US$89k
Mar 31 2019	n/a	n/a	US$52k
Dec 31 2018	US$200k	US$200k	US$9k
Sep 30 2018	n/a	n/a	US$337k
Jun 30 2018	n/a	n/a	US$319k
Mar 31 2018	n/a	n/a	US$292k
Dec 31 2017	US$149k	US$149k	US$289k

Compensation vs Market: Suren's total compensation ($USD414.23K) is below average for companies of similar size in the US market ($USD674.64K).

Compensation vs Earnings: Suren's compensation has increased whilst the company is unprofitable.

CEO

Suren Ajjarapu (52 yo)

10.3yrs

Tenure

US$414,231

Compensation

Mr. Surendra K. Ajjarapu, also known as Suren, serves as CEO & Director of Integrated Wellness Acquisition Corp since February 12, 2024. He serves as Founder, Chairman, CEO & Director at Trxade, Inc. He se...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Surendra Ajjarapu	Founder	10.3yrs	US$414.23k	27.46% $ 2.3m
Prashant Patel	Founder	10.3yrs	US$157.04k	26.24% $ 2.2m
Ramesh Kenchappa	Chief Scientific Officer	9.6yrs	no data	no data
David Saslow	Inhouse Counsel	no data	no data	no data
Jariel Morales	Executive Vice President	7yrs	no data	no data
Shafaat Pirani	Executive Vice President of Alliance Pharma Solutions	no data	no data	no data

9.9yrs

Average Tenure

Experienced Management: MEDS's management team is seasoned and experienced (9.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Surendra Ajjarapu	Founder	10.3yrs	US$414.23k	27.46% $ 2.3m
Prashant Patel	Founder	10.3yrs	US$157.04k	26.24% $ 2.2m
Michael Peterson	Independent Director	1.3yrs	US$96.25k	no data
Candice Beaumont	Director	less than a year	no data	no data
A. Newell	Independent Director	1.6yrs	US$59.35k	no data
Donald Anderson	Member of Advisory Board	8.8yrs	no data	no data
Donald Fell	Independent Director	10.3yrs	US$129.25k	0.41% $ 34.6k

8.8yrs

Average Tenure

56.5yo

Average Age

Experienced Board: MEDS's board of directors are considered experienced (8.8 years average tenure).

TRxADE HEALTH Management

Management criteria checks 3/4

Key information

Recent management updates

TRxADE HEALTH, Inc., Annual General Meeting, Jun 15, 2023

TRxADE HEALTH, INC Announces Board Changes

Less than half of directors are independent

Less than half of directors are independent

Trxade Health, Inc. Appoints Mr. Jeff Newell to Its Board of Directors, Member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

TRxADE HEALTH, Inc. Announces the Resignation of Christine L. Jennings as Member of the Board of Directors

Recent updates

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Superlatus Foods, Inc. acquired Superlatus, Inc from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.000001 million.

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding agreement to acquire The Urgent Company, Inc. from Perfect Day, Inc.

TRxADE HEALTH, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRxADE HEALTH Receives Non-Compliance Notice from Nasdaq

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding letter of intent to acquire Superlatus, Inc.

TRxADE HEALTH, Inc., Annual General Meeting, Jun 15, 2023

TRxADE HEALTH Submits Hearing Request to the Nasdaq Hearings Panel

TRxADE HEALTH Receives A Delist Determination Letter from Nasdaq

Wood Sage, LLC entered into a membership interest purchase agreement to acquire Community Specialty Pharmacy, LLC from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.1 million.

Wood Sage, LLC entered into Membership Interest Purchase Agreement to acquire Alliance Pharma Solutions, LLC for $0.125 million.

TRxADE HEALTH, INC Announces Board Changes

TRxADE HEALTH Receives Written Notice from Nasdaq

Consensus forecasts updated

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

TRxADE HEALTH, Inc. to Report Q3, 2022 Results on Nov 07, 2022

No longer forecast to breakeven

Price target decreased to US$3.25

TRxADE HEALTH Provides Update on Retaining Compliance Regarding Listing

Less than half of directors are independent

TRxADE Health prices of $1.8M stock offering

Trxade Health, Inc. Appoints Mr. Jeff Newell to Its Board of Directors, Member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

TRxADE HEALTH, Inc. Announces the Resignation of Christine L. Jennings as Member of the Board of Directors

TRxADE Health launches next day delivery services via Trxade prime plus program

TRxADE Health proposes public stock offering

TRxADE HEALTH, Inc. Appoints Jeff Newell to Its Advisory Board

TRxADE HEALTH Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Trxade Group GAAP EPS of -$0.13 misses by $0.05, revenue of $3.3M beats by $0.37M

TRxADE HEALTH, Inc. to Report Q2, 2022 Results on Jul 25, 2022

Consensus EPS estimates fall by 19%

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$5.92

TRxADE HEALTH, Inc. to Report Q1, 2022 Results on May 09, 2022

TRxADE HEALTH, Inc., Annual General Meeting, Jun 02, 2022

Consensus EPS estimates fall by 54%

TRxADE HEALTH, Inc. Announces Management Changes

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Will TRxADE HEALTH (NASDAQ:MEDS) Spend Its Cash Wisely?

Price target decreased to US$7.50

Here's Why We're Watching TRxADE HEALTH's (NASDAQ:MEDS) Cash Burn Situation

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.017 profit in 3Q 2020)

Need To Know: Analysts Just Made A Substantial Cut To Their TRxADE HEALTH, Inc. (NASDAQ:MEDS) Estimates

Price target decreased to US$8.75

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$0.072 loss in 2Q 2020)

Pharma Pain Points - Trxade CEO Suren Ajjarapu (Video)

SpartanNash and Bonum Health join hands to provide telemedicine services

Independent Director Pamela Tenaerts has left the company

Independent Director Michael Peterson has left the company

Shareholders Will Probably Hold Off On Increasing Trxade Group, Inc.'s (NASDAQ:MEDS) CEO Compensation For The Time Being

Trxade Group, Inc. (NasdaqCM:MEDS) entered into an agreement to acquire QualityCare Pharmacies.

Price target decreased to US$10.00

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.026 profit in 1Q 2020)

Earnings Release: Here's Why Analysts Cut Their Trxade Group, Inc. (NASDAQ:MEDS) Price Target To US$10.00

Time To Worry? Analysts Just Downgraded Their Trxade Group, Inc. (NASDAQ:MEDS) Outlook

Full year 2020 earnings released: US$0.33 loss per share (vs US$0.048 loss in FY 2019)

Price target raised to US$12.17

Did Business Growth Power Trxade Group's (NASDAQ:MEDS) Share Price Gain of 143%?

New 90-day high: US$6.36

Price target raised to US$12.17

New 90-day low: US$4.56

Third quarter earnings released

Trxade Group, Inc. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: US$5.05